Dr. Emilia Torlakovic obtained her M.D. at the University of Zagreb and her Ph.D. at the University of Oslo. She is board certified by The American Board of Pathology in Anatomic and Clinical Pathology with subspecialty boards in Hematopathology. She is a founding member of the NordiQC, has co-founded CIQC, and also founded Canadian Biomarker Quality Assurance and CBQAReadout.ca academic QA programs, which she is currently directing. Dr. Torlakovic is the Chair of the National Standards Committee for High Complexity Testing of the Canadian Association of Pathologists. She was/is a member of the ASCO/CAP expert panel that published guidelines for hormone receptor testing in breast cancer in 2010 and also an updated guideline in 2020. She is the President of the International Society for Immunohistochemistry and Molecular Morphology and a Board Member of the International Quality Network for Pathology. She is currently a Division Head of Laboratory Hematology in Saskatoon.
Develop a plan for the implementation of a new predictive biomarker assay based on current international guidelines using PD-L1 as an example.
Select an optimal assay for their local environment (LDT vs. CDx).
Integrate the results of test performance characteristics derived from participation in EQA programs as prospective evidence of optimal assay performance.
Integrate readout validation into assay development as well as maintenance of ongoing proficiency for different PD-L1 readouts/scoring algorithms.